Literature DB >> 27347351

Distinct roles of parafibromin in the extracellular environment, cytoplasm and nucleus of osteosarcoma cells.

Jia-Jun Zhu1, Yan Cui1, Kai Cui1, Xi Li1, Zhi-Yu Zhang1.   

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor. Parafibromin-inactivating mutations have been reported in various malignancies. In this study, the effects and relevant mechanisms of ectopic parafibromin expression were identified in the extracellular environment, cytoplasm and nucleus of OS cells. Our results indicate that parafibromin located in the nucleus can induce apoptosis and G1 phase arrest in OS cells. Parafibromin was found to suppress the MEK/ERK and PI3K/AKT signaling pathways, leading to activation of caspase 3 and caspase 9. Overall, these studies demonstrate the anti-tumor activity of parafibromin in the OS cell line, and provide insight into relevant mechanisms that may lead to novel treatments for OS.

Entities:  

Keywords:  Parafibromin; apoptosis; cell cycle; osteosarcoma cell; proliferation

Year:  2016        PMID: 27347351      PMCID: PMC4891456     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  15 in total

1.  Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin.

Authors:  Michael A Hahn; Deborah J Marsh
Journal:  Oncogene       Date:  2005-09-15       Impact factor: 9.867

2.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.

Authors:  J D Carpten; C M Robbins; A Villablanca; L Forsberg; S Presciuttini; J Bailey-Wilson; W F Simonds; E M Gillanders; A M Kennedy; J D Chen; S K Agarwal; R Sood; M P Jones; T Y Moses; C Haven; D Petillo; P D Leotlela; B Harding; D Cameron; A A Pannett; A Höög; H Heath; L A James-Newton; B Robinson; R J Zarbo; B M Cavaco; W Wassif; N D Perrier; I B Rosen; U Kristoffersson; P D Turnpenny; L-O Farnebo; G M Besser; C E Jackson; H Morreau; J M Trent; R V Thakker; S J Marx; B T Teh; C Larsson; M R Hobbs
Journal:  Nat Genet       Date:  2002-11-18       Impact factor: 38.330

4.  Parafibromin expression is an independent prognostic factor for colorectal carcinomas.

Authors:  Hua-chuan Zheng; Zheng-li Wei; Xiao-yan Xu; Xiao-cui Nie; Xue Yang; Hiroyuki Takahashi; Yasuo Takano
Journal:  Hum Pathol       Date:  2011-02-11       Impact factor: 3.466

5.  The clinicopathological significances and biological functions of parafibromin expression in head and neck squamous cell carcinomas.

Authors:  Zhuo Zhang; Xue-Feng Yang; Ke-Qiang Huang; Li Ren; Wen-Feng Gou; Dao-Fu Shen; Shuang Zhao; Hong-Zhi Sun; Yasuo Takano; Hua-Chuan Zheng
Journal:  Tumour Biol       Date:  2015-07-01

6.  Transcriptional repression of tumor suppressor CDC73, encoding an RNA polymerase II interactor, by Wilms tumor 1 protein (WT1) promotes cell proliferation: implication for cancer therapeutics.

Authors:  Mohammad Iqbal Rather; Shivananda Swamy; Kodaganur S Gopinath; Arun Kumar
Journal:  J Biol Chem       Date:  2013-11-20       Impact factor: 5.157

7.  The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene.

Authors:  Ling Lin; Jian-Hua Zhang; Leelamma M Panicker; William F Simonds
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-05       Impact factor: 11.205

8.  IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.

Authors:  Olivia Bibollet-Bahena; Guillermina Almazan
Journal:  J Neurochem       Date:  2009-03-28       Impact factor: 5.372

9.  Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.

Authors:  Peter P Truran; Sarah J Johnson; Richard D Bliss; Thomas W J Lennard; Sebastian R Aspinall
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

10.  Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas.

Authors:  Hua-Chuan Zheng; Hiroyuki Takahashi; Xiao-Han Li; Takuo Hara; Shinji Masuda; Yi-Fu Guan; Yasuo Takano
Journal:  Virchows Arch       Date:  2007-12-14       Impact factor: 4.064

View more
  5 in total

1.  Parafibromin Is Highly Expressed in Hepatocellular Carcinoma and Its Expression Correlates with Poor Prognosis.

Authors:  Min-Kyung Kim
Journal:  J Clin Med       Date:  2022-03-23       Impact factor: 4.241

2.  The clinicopathological and prognostic significances of CDC73 expression in cancers: a bioinformatics analysis.

Authors:  Hua-Chuan Zheng; Bao-Cheng Gong; Shuang Zhao
Journal:  Oncotarget       Date:  2017-08-24

3.  The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway.

Authors:  Yazhuo Liu; Ruoyu Wang; Lichuan Zhang; Jianhua Li; Keli Lou; Bingyin Shi
Journal:  Oncol Lett       Date:  2017-04-13       Impact factor: 2.967

4.  The in vitro and vivo effects of nuclear and cytosolic parafibromin expression on the aggressive phenotypes of colorectal cancer cells: a search of potential gene therapy target.

Authors:  Hua-Chuan Zheng; Jia-Jie Liu; Jing Li; Ji-Cheng Wu; Lei Yang; Gui-Feng Zhao; Xin Zhao; Hua-Mao Jiang; Ke-Qiang Huang; Zhi-Jie Li
Journal:  Oncotarget       Date:  2017-04-04

Review 5.  The roles of the tumor suppressor parafibromin in cancer.

Authors:  Hua-Chuan Zheng; Hang Xue; Cong-Yu Zhang
Journal:  Front Cell Dev Biol       Date:  2022-09-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.